Late preterm infant

American Regent Introduces Potassium Phosphates, USP; FDA-Approved and "AP" Rated¹

Retrieved on: 
Thursday, October 19, 2023
Cardiac arrest, ECG, Injection, Seizure, Arrhythmia, Nephrocalcinosis, Hypercalcaemia, Infant, Kidney, Continuity, Risk, Hyperkalemia, Death, Parenteral nutrition, Child, Potassium, Lactation, Thrombosis, Acute kidney injury, Milk, Tetany, Toxicity, Phosphate, Patient, Central nervous system, Bolus, Hyperphosphatemia, Hypophosphatemia, Hypotension, Hypocalcemia, Tubing (recreation), Pulmonary embolism, Use, Aluminium, Administration, Late preterm infant, QT, Calcium, Ketoacidosis, Phosphorus, Birth control, Medical device, Pharmaceutical industry, Magnesium deficiency

In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.

Key Points: 
  • In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.
  • Vein Damage and Thrombosis: Potassium Phosphates Injection must be diluted and administered in intravenous fluids or used as an admixture in parenteral nutrition.
  • You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
  • You are encouraged to report adverse drug events (ADEs) to American Regent:
    ADEs may also be reported to the FDA:

Astarte Medical and Tiny Health Join Forces to Optimize Gut Health for Vulnerable Preterm Infants

Retrieved on: 
Thursday, September 21, 2023
Partnership, Asthma, Obesity, Newcastle University, NICU, Gestational age, Parent, Dermatitis, Late preterm infant, Survival, Nutrient, Necrotizing enterocolitis, Fungus, Mother, Data, Risk, Immune system, Parasitism, Growth, ICU, Bacteria, Probiotic, Virus, Birth control, Dietary supplement

YARDLEY, Pa. and AUSTIN, Texas, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Astarte Medical, a leading pediatric clinical intelligence company, is forming a joint venture with Tiny Health, makers of gut microbiome tests for babies and expecting parents. The partners have agreed to develop a clinical-facing technology solution to support gut health for preterm and critically ill infants receiving care in the neonatal ICU.

Key Points: 
  • The partners have agreed to develop a clinical-facing technology solution to support gut health for preterm and critically ill infants receiving care in the neonatal ICU.
  • "By partnering with Astarte Medical, we're extending our solution to support infants and families at their most vulnerable time.
  • In a previous multi-center microbiome study, Astarte Medical identified six gut community types among nearly 300 preterm infants born under 34 weeks gestational age.
  • Tiny Health will offer NICU parents the option to test their infants post-discharge to extend the understanding of the maturity patterns of infants born preterm.

Prolacta Bioscience Recognizes Advances in Preterm Care During NICU Awareness Month

Retrieved on: 
Tuesday, September 19, 2023
Breast Cancer Awareness Month, University, Pediatrics, BPD, NICU, Hospital, Late preterm infant, VLBW, Nicu Ceaușescu, Infant, Retinopathy, Premature, Risk, Master of Science, BioMed Central, ROP, Intensive care unit, Heart rate, Health, Bronchopulmonary dysplasia, NEC, Dairy, Birth control, Health insurance, MD

DUARTE, Calif., Sept. 19, 2023 /PRNewswire/ -- There have been incredible breakthroughs in neonatal care over the last decade, with premature infants born as early as 22 weeks now surviving and thriving. From heart rate monitoring to lung therapies, one of the biggest changes in the NICU has been how these fragile, premature infants are fed. This Neonatal Intensive Care Unit (NICU) Awareness Month, Prolacta Bioscience® recognizes how proper care, including critical nutrition in the NICU — with 100% human milk-based nutrition — has improved the health and well-being of preterm infants.

Key Points: 
  • From heart rate monitoring to lung therapies, one of the biggest changes in the NICU has been how these fragile, premature infants are fed.
  • This Neonatal Intensive Care Unit (NICU) Awareness Month, Prolacta Bioscience ® recognizes how proper care, including critical nutrition in the NICU — with 100% human milk-based nutrition — has improved the health and well-being of preterm infants.
  • Today, the world's leading clinicians and NICUs offer Prolacta's human milk-based nutritional products as the standard of care because they have been shown to reduce some of the most serious complications of prematurity.
  • "NICU Awareness Month reminds us to take a step back and reflect upon how far we've come in neonatal care over the last decade.

Global Enteral Feeding Formulas Market Trends Analysis Report 2023-2030: Advancements in Disease-Specific Formulas Drive Enteral Feeding Market - ResearchAndMarkets.com

Retrieved on: 
Friday, August 18, 2023
Health, Medical Supplies, Medical Devices, Bronchopulmonary dysplasia, Medicaid, Drug development, BPD, Prevalence, Diabetes, Malnutrition, Late preterm infant, NCBI, NPO Splav, Cancer, Nutrient, HEN, USD, Movement, Patient, Non-governmental organization, Risk, Treatment, Child, UN, Preterm birth, Immune system, Cystic fibrosis, ROP, Conditional sentence, Growth, ASPEN, Retinopathy, Liver failure, Retail, Dietary supplement, Premature

The "Enteral Feeding Formulas Market Size, Share & Trends Analysis Report By Product, By Flow Type, By Stage, By Indication, By End-user, By Sales Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Enteral Feeding Formulas Market Size, Share & Trends Analysis Report By Product, By Flow Type, By Stage, By Indication, By End-user, By Sales Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global enteral feeding formulas market size is expected to reach USD 10.5 billion by 2030, expanding at 5.5% CAGR from 2023 to 2030
    Increasing incidences of targeted diseases and advancements in drug development are expected to drive the demand for disease-specific formulas.
  • Clinical nutrition is increasingly used for the personalized treatment of diseases, such as cancer and cystic fibrosis.
  • Standard formula was the largest product segment, accounting for 57.0% of the market share in 2022, in terms of revenue.

Children's Hospital of Orange County neonatologist Dr. Terrie Inder's study on preterm brains published in New England Journal of Medicine

Retrieved on: 
Wednesday, August 2, 2023
The New England Journal of Medicine, NICU, Orange County, Boston Children's Hospital, Late preterm infant, Human, Research, Brain, Rehabilitation, Child, Disability studies, Infant, MRI, Magnetic resonance imaging, Preterm birth, Neurology, White matter, Hospital, Environment, CHOC, Injury, Medical imaging, NEJM

Dr. Terrie Inder , an expert on the newborn brain and director of the Center for Neonatal Research at Children's Hospital of Orange County ( CHOC ), is the lead author of "Defining the Neurological Consequences of Preterm Birth."

Key Points: 
  • Dr. Terrie Inder , an expert on the newborn brain and director of the Center for Neonatal Research at Children's Hospital of Orange County ( CHOC ), is the lead author of "Defining the Neurological Consequences of Preterm Birth."
  • The paper provides a comprehensive study of what is known about neurological consequences of preterm birth, as well as recognizes the gaps.
  • Globally, an estimated 15 million infants are born preterm (less than 37 weeks' gestation).
  • Dr. Inder's paper focuses on brain injuries and long-term adverse neurologic effects of preterm babies and very preterm babies (those born between 32 weeks and 26 weeks).

FDA Approves New Drug to Prevent RSV in Babies and Toddlers

Retrieved on: 
Monday, July 17, 2023
Vaccine, Infection, China Biologic Products, Bronchiolitis, Ventricular septal defect, Pediatrics, Office of Inspector General, U.S. Department of Health and Human Services, Hospital, Center for Drug Evaluation and Research, Gestational age, Human services, Public, Late preterm infant, Pediatrics (journal), American Academy, Food, Cosmetics, Multimedia, Coagulopathy, History, AstraZeneca, Animal, Ill, Rash, Respiratory syncytial virus, Incidence, Excipient, RSV, Dietary supplement, Premature, Immunoglobulin G, Risk, Anaphylaxis, MA, Heated tobacco product, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, Pneumonia, Safety, Birth control, Pharmaceutical industry, Nirsevimab

"Today's approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system."

Key Points: 
  • "Today's approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system."
  • Premature infants, and those with chronic lung disease of prematurity or significant congenital heart disease, are at highest risk for severe RSV disease.
  • One dose of Beyfortus, administered as a single intramuscular injection prior to or during RSV season, may provide protection during the RSV season.
  • The safety and pharmacokinetic data from Trial 05 provided evidence for the use of Beyfortus to prevent MA RSV LRTI in this population.

New Study Shows Prolacta's Human Milk-Based Nutritional Fortifiers Save Hospital NICUs Up to $3.4M Annually

Retrieved on: 
Tuesday, June 27, 2023
Hospice and palliative medicine, Exclusive, University, Pediatrics, BPD, NICU, Late preterm infant, VLBW, Retinopathy, Hospital, Premature, Master of Science, BioMed Central, ROP, Infant, Bronchopulmonary dysplasia, NEC, Nursing, Birth control, Health insurance, MD

DUARTE, Calif., June 27, 2023 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, today announced a peer-reviewed report demonstrating significant annual cost savings that ranged from $500,000 to $3.4 million per hospital after the implementation of Prolacta's Exclusive Human Milk Diet (Prolacta's EHMD) for preterm infants in the neonatal intensive care unit (NICU).

Key Points: 
  • DUARTE, Calif., June 27, 2023 /PRNewswire/ -- Prolacta Bioscience , the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, today announced a peer-reviewed report demonstrating significant annual cost savings that ranged from $500,000 to $3.4 million per hospital after the implementation of Prolacta's Exclusive Human Milk Diet (Prolacta's EHMD) for preterm infants in the neonatal intensive care unit (NICU).
  • NICU leaders from seven U.S. hospitals varying in size, geographic setting, patient population, and funding levels contributed to the publication in BMC Pediatrics titled "Implementing an Exclusive Human Milk Diet for Preterm Infants: Real-World Experience in Diverse NICUs."
  • The study found:
    Of the five hospitals reporting financial data, all realized significant cost avoidance after implementing Prolacta's EHMD, with savings ranging from $515,113 to $3,369,515 per institution annually from a reduction in comorbidities and shorter lengths of stay among very low birth weight (VLBW) infants.1
    Implementation of Prolacta's EHMD resulted in a reduction in the total (medical and surgical) necrotizing enterocolitis (NEC) rate, regardless of the size or level of care of the NICU, as well as reductions in bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and late-onset sepsis — all common complications of prematurity.1
    VLBW infants fed Prolacta's EHMD also experienced shorter NICU stays at five of the seven hospitals, savings ranging from $307,916 to $2,520,000 per institution annually.1
    The study emphasizes that the cost of Prolacta's EHMD represents a fraction of the usual cost of care for a VLBW infant — approximately $12,500 per infant for an EHMD over a 90-day NICU stay, compared to a total NICU cost of $693,000 to $774,000 for 90 days, depending on level of care.2,3
    "This study provides real-world evidence that an EHMD is not only effective in reducing comorbidities in very preterm infants but also saves money regardless of the institution's size or level of care," said lead author Jonathan R. Swanson, MD, MSc, of the University of Virginia Children's Hospital in Charlottesville.

Medela Concludes Global Breastfeeding Symposium with Key Takeaways in Lactation Science to Inform Clinical Practice

Retrieved on: 
Tuesday, June 27, 2023
NICU, LARS, Lactation, Imperial College London, Survival, University of California, San Diego, Quality, Science, Mother, Milk, University, Hospital, Great Western Hospital, Infant, Great Western Hospitals NHS Foundation Trust, AU, Pediatrics, Late preterm infant, Physiology, Research, Obstetrics, Knowledge, European Association of Urology, British Association of Perinatal Medicine, Initiation, Neonatology, Social support, Government, Translation, OMM, Standard of care, The Hospital, Nursing credentials and certifications, University of Pennsylvania School of Nursing, Medicine, Family, Breast milk, Partnership, Woman, Health, Qi, Nursing, Dairy, Birth control

Switzerland, Baar, June 27, 2023 (GLOBE NEWSWIRE) -- Medela, the brand trusted by millions of moms*, concluded its 16th Global Breastfeeding and Lactation Symposium, focused on advancing lactation science to improve care.

Key Points: 
  • Switzerland, Baar, June 27, 2023 (GLOBE NEWSWIRE) -- Medela, the brand trusted by millions of moms*, concluded its 16th Global Breastfeeding and Lactation Symposium, focused on advancing lactation science to improve care.
  • “By bringing together top minds in lactation science from around the world, we are able to further our shared goal of improving maternal and infant health outcomes,” said Annette Brüls, CEO of  Medela worldwide.
  • “Medela’s Symposium brings new lactation evidence to clinician leaders who will translate the science to the bedside for families around the world.
  • On day two of the symposium the healthcare experts on-site took these findings into curated workshops with the goal of translating them into clinical practice.

Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Retrieved on: 
Monday, June 5, 2023
Biotechnology, Pharmaceutical, Health, FDA, Baby, Maternity, Consumer, Clinical Trials, Other Health, Late preterm infant, Therapy, BPD, Patient, Bronchopulmonary dysplasia, Inflammation, Risk, Pharmaceutical industry, Health insurance

These infants, born at 23 to

Key Points: 
  • These infants, born at 23 to
  • As many as 2.5 million very preterm infants globally are at risk of developing BPD from lung damage caused by mechanical ventilation and oxygen support.
  • The Phase 1b trial is a randomized, blinded, air-sham controlled study to establish the safety and tolerability of zelpultide alfa.
  • The FDA and European Medicines Agency have granted orphan drug status to zelpultide alfa.

Mount Sinai Awarded Grant to Assess Music's Impact on Well-Being, Depression

Retrieved on: 
Thursday, April 27, 2023
DSM-IV codes, River Music Experience, Music, Depression, Life, Suicide, Parent, Music therapy, Calendar, Late preterm infant, Ministry of Women and Vulnerable Populations, Quality of life, National Endowment for the Arts, COVID, Mount Sinai, New York Academy of Medicine, Thought, DA, Pain, Student, Cooper Union, NEA, Patient, Risk, Third Street Music School Settlement, LCAT, Affect, Neurology, Nightclub, Entertainment, Nursing, Medicine

NEW YORK, April 27, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System Assessment of Music Experiences in Navigating Depression (AMEND Lab) at the Louis Armstrong Center for Music and Medicine has received a grant from the National Endowment for the Arts (NEA) to investigate how music and music therapy can influence mood and alter depression symptoms across vulnerable populations.

Key Points: 
  • "A cornerstone of the study is 'social prescribing,' a concept that is widely used in Europe," Dr. Loewy explained.
  • "It involves thinking of music less as a recreational activity, and more as a foundational prescription for everyday life.
  • The study will also involve working one-on-one with individuals with clinical depression to explore in depth how music therapy impacts their depression.
  • Additional partners in the NEA-funded study include Cooper Union, Third Street Music School, Young Adults Institute, and Lincoln Center Moments.